Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice

Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice

Abstract Vaccines that efficiently target severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent for coronavirus disease (COVID-19), are the best means for controlling viral spread. This study evaluated the efficacy of the COVID-19 vaccine S-268019-b, which comprises the...

Full description

Bibliographic Details
Main Authors: Tomoyuki Homma, Noriyo Nagata, Masayuki Hashimoto, Naoko Iwata-Yoshikawa, Naomi M. Seki, Nozomi Shiwa-Sudo, Akira Ainai, Keiji Dohi, Eiji Nikaido, Akiko Mukai, Yuuta Ukai, Takayuki Nakagawa, Yusuke Shimo, Hiroki Maeda, Seiki Shirai, Miwa Aoki, Takuhiro Sonoyama, Mamoru Sato, Masataka Fumoto, Morio Nagira, Fumihisa Nakata, Takao Hashiguchi, Tadaki Suzuki, Shinya Omoto, Hideki Hasegawa
Format: Article
Language:English
Published: Nature Portfolio 2022-12-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-25418-5

Similar Items

Similar Items